Measured Wealth Private Client Group LLC Sells 547 Shares of Johnson & Johnson (NYSE:JNJ)

view original post

Measured Wealth Private Client Group LLC lessened its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 8.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,663 shares of the company’s stock after selling 547 shares during the period. Measured Wealth Private Client Group LLC’s holdings in Johnson & Johnson were worth $1,004,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Family CFO Inc bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $26,000. Steward Financial Group LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $34,000. Joseph P. Lucia & Associates LLC bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at $38,000. Advocacy Wealth Management Services LLC raised its position in shares of Johnson & Johnson by 41.4% during the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after acquiring an additional 67 shares during the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $49,000. Institutional investors own 68.78% of the company’s stock.

Johnson & Johnson Stock Down 0.3 %

Shares of JNJ stock opened at $173.91 on Tuesday. The stock has a market cap of $457.63 billion, a price-to-earnings ratio of 25.31, a PEG ratio of 3.32 and a beta of 0.59. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The firm’s 50-day moving average is $175.84 and its 200-day moving average is $174.50.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The business had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. During the same quarter last year, the business posted $2.48 EPS. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Sell-side analysts predict that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.60%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 65.79%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on JNJ shares. The Goldman Sachs Group boosted their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. Citigroup decreased their price target on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 13th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 17th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Insider Buying and Selling at Johnson & Johnson

In related news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CAO Robert J. Decker sold 8,462 shares of the business’s stock in a transaction that occurred on Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.